Observational and Cross-sectional Study to Assess the Sociodemographic and Clinical Characteristics of Patients Treated With RIVAROXABAN in the Context of Routine Clinical Practice of Spanish Haematologists, Cardiologists and Internists (HEROIC Study)
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms HEROIC
- Sponsors Bayer
- 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Mar 2015 Planned End Date changed from 1 Jul 2015 to 1 May 2015, as reported by ClinicalTrials.gov.
- 11 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.